Methylation Analysis of Rb, P16, MGMT, and hMLH-1in Mucoepidermoid Carcinomas. A Pilot Study
DOI:
https://doi.org/10.15517/1hf9vs72Keywords:
Methylation; Mucoepidermoid carcinoma; RB; MGMT; hMLH-1.Abstract
Mucoepidermoid carcinoma (MC) is the most common malignant epithelial neoplasm in the salivary glands. This neoplasm has varying proportions of mucous, epidermoid, intermediate, columnar, and clear cells. MCs have been associated with CRTC1-MAML2 genes; however, their pathogenesis is uncertain. Recently, epigenetic changes have been considered a possible aetiologic factor. To identify the methylation state of RB, P16, MGMT, and hMLH genes in the three severity grades of MC were used five MCs and one healthy minor salivary gland as a control group (CG) obtained from the Pathology and Oral Medicine Laboratory and analyzed using MS-PCR to compare the presence or absence of methylation in promotor regions. The Kruskal-Wallis test was performed, with p≤0.05 considered significant. CG was employed as the normalizer of methylation levels. All assays were performed in triplicate. The mean age of our population was 52.6±18.6 years old; the total population was female and included 2 low grade, 2 intermediate grade, and 1 high grade levels of severity. When comparing the methylation status of the three histopathological grades of MC against the control, statistically significant differences were observed in Rb-M, MGMT-M, and hMLH-1-NM for high-grade severity, with p values of 0.03, 0.05, and 0.04, respectively. Methylation is a possible mechanism for pathogenesis processing of high-grade MC. However, a larger sample population is necessary to validate this finding.
Downloads
References
Granados R.H., Méndez C.M., López P.G., Aldape-Barrios B. Carcinoma mucoepidermoide. Revista de la Asociación Dental Mexicana. 2010; 67 (4): 181-4.
Avila R.E., Samar M.E., Fonseca I., Olmedo L., Asís O.G., Ferraris R. Carcinoma Mucoepidermoide de glándulas salivales: factores pronósticos histológicos e inmunohistoquímicos. International Journal of Morphology. 2011; 29 (2): 455-62. DOI: https://doi.org/10.4067/S0717-95022011000200026
Tronick E., Hunter R.G. Waddington, dynamic systems, and epigenetics. Front Behav Neurosci. 2016; 10: 107. DOI: https://doi.org/10.3389/fnbeh.2016.00107
Bird A. Perceptions of epigenetics. Nature. 2007; 447 (7143): 396. DOI: https://doi.org/10.1038/nature05913
Feinberg A.P., Tycko B. The history of cancer epigenetics. Nat Rev Cancer. 2004; 4 (2): 143-53. DOI: https://doi.org/10.1038/nrc1279
Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002; 3 (6): 415-28. DOI: https://doi.org/10.1038/nrg816
Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002; 16 (1): 6-21. DOI: https://doi.org/10.1101/gad.947102
Langevin S.M., Eliot M., Butler R.A., Cheong A., Zhang X., McClean M.D., et al. CpG island methylation profile in non-invasive oral rinse samples is predictive of oral and pharyngeal carcinoma. Clin Epigenetics. 2015; 7 (1): 1-12. DOI: https://doi.org/10.1186/s13148-015-0160-7
Rodríguez-Paredes M., Esteller M. Cancer epigenetics reaches mainstream oncology. Nat Med. 2011; 17 (3): 330-9. DOI: https://doi.org/10.1038/nm.2305
Tsakogiannis D., Moschonas G.D., Daskou M., Stylianidou Z., Kyriakopoulou Z., Kottaridi C., et al. Polymorphic variability in the exon 19 of the RB1 gene and its flanking intronic sequences in HPV16-associated precancerous lesions in the Greek population. J Med Microbiol. 2018; 67 (11): 1638-44. DOI: https://doi.org/10.1099/jmm.0.000843
de Souza A.A,. Altemani A., Passador-Santos F., Turssi C.P., de Araujo N.S., de Araújo V.C., et al. Dysregulation of the Rb pathway in recurrent pleomorphic adenoma of the salivary glands. Virchows Archiv. 2015; 467 (3): 295-301.
Zhang J.C., Gao B., Yu Z.T., Liu X.B., Lu J., Xie F., et al. Promoter hypermethylation of p14 ARF, RB, and INK4 gene family in hepatocellular carcinoma with hepatitis B virus infection. Tumor Biology. 2014 Mar 1; 35 (3): 2795-802. DOI: https://doi.org/10.1007/s13277-013-1372-0
Guo L., Huang C., Qj J. CLINICAL STUDY Aberrant promoter hypermethylation of p16, survivin, and retinoblastoma in gastric cancer. Science Citation Index Expanded and in Journal Citation Reports/Science Edition Bratisl Med J [Internet]. 2017; 118 (3). Available from: www.elis.sk. DOI: https://doi.org/10.4149/BLL_2017_033
de Souza A.A., Altemani A., Passador-Santos F., Turssi C.P., de Araujo N.S., de Araújo V.C., et al. Dysregulation of the Rb pathway in recurrent pleomorphic adenoma of the salivary glands. Virchows Archiv. 2015; 467 (3): 295-301. DOI: https://doi.org/10.1007/s00428-015-1804-x
Jiao Y., Feng Y., Wang X. Regulation of tumor suppressor gene CDKN2A and encoded p16-INK4a protein by covalent modifications. Biochemistry (Moscow). 2018; 83 (11): 1289-98. DOI: https://doi.org/10.1134/S0006297918110019
Foulkes W.D., Flanders T.Y., Pollock P.M., Hayward N.K. The CDKN2A (p16) gene and human cancer. Molecular medicine. 1997; 3 (1): 5-20. DOI: https://doi.org/10.1007/BF03401664
Natsume A., Ishii D., Wakabayashi T., Tsuno T., Hatano H., Mizuno M., et al. IFN-β down-regulates the expression of DNA repair gene MGMT and sensitizes resistant glioma cells to temozolomide. Cancer Res. 2005; 65 (17): 7573-9. DOI: https://doi.org/10.1158/0008-5472.CAN-05-0036
Esteller M., Risques R.A., Toyota M., Capella G., Moreno V., Peinado M.A., et al. Promoter hypermethylation of the DNA repair gene O6-methylguanine-DNA methyltransferase is associated with the presence of G: C to A: T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001; 61 (12): 4689-92.
Esteller M., Garcia-Foncillas J., Andion E., Goodman S.N., Hidalgo O.F., Vanaclocha V., et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine. 2000; 343 (19): 1350-4. DOI: https://doi.org/10.1056/NEJM200011093431901
Guida M., Sanguedolce F., Bufo P., di Spiezio Sardo A., Bifulco G., Nappi C., et al. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol [Internet]. 2009; 30 (3): 267-70. Available from: http://europepmc.org/abstract/MED/19697618
YÁÑEZ J.H.S. Análisis del Estado de metilación del ADN y su relación con Modificaciones de Histonas del promotor de los Genes MLH1, p16 y NKX2-3, en diferentes tipos de cáncer. Universidad de Concepción; 2014.
Zare M., Jafari-Nedooshan J., Jafari M., Neamatzadeh H., Abolbaghaei S.M., Foroughi E., et al. Relevance of hMLH1-93G> A, 655A> G and 1151T> A polymorphisms with colorectal cancer susceptibility: a meta-analysis based on 38 case-control studies. Rev Assoc Med Bras. 2018; 64: 942-51. DOI: https://doi.org/10.1590/1806-9282.64.10.942
Michailidi C., Theocharis S., Tsourouflis G., Pletsa V., Kouraklis G., Patsouris E., et al. Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma. Exp Biol Med. 2015; 240 (12): 1599-605. DOI: https://doi.org/10.1177/1535370215583800
Aviso de privacidad integral para pacientes. Unam.mx. [citado el 12 de agosto de 2022]. Disponible en: https://www.odonto.unam.mx/sites/default/files/inline-files/1.AP_Integral-Fac_Esc_Inst_Centros%20%20PARA%20PACIENTES%20-.pdf
Adel K. El-Naggar, Jhon K.C chan, Jennifer R. Grandis, Takashi Takata PJS. WHO Classification of Head and Neck Tumors. 4ta ed. International Aency for Research on Cancer, editor. Lyon, Francia; 2017. 347 p.
Li L.C. and Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002 Nov; 18 (11): 1427-31. PMID: 12424112. MethPrimer. DOI: https://doi.org/10.1093/bioinformatics/18.11.1427
Chkheidze R., Raisanen J., Gagan J., Richardson T.E., Pinho M.C., Raj K., et al. Alterations in the RB Pathway With Inactivation of RB1 Characterize Glioblastomas With a Primitive Neuronal Component. J Neuropathol Exp Neurol [Internet]. 2021 Dec 1; 80 (12): 1092-8. Available from: https://doi.org/10.1093/jnen/nlab109 DOI: https://doi.org/10.1093/jnen/nlab109
Zhou Y., Jin X., Ma J., Ding D., Huang Z., Sheng H., et al. HDAC5 Loss Impairs RB Repression of Pro-Oncogenic Genes and Confers CDK4/6 Inhibitor Resistance in Cancer. Cancer Res [Internet]. 2021 Mar 15; 81 (6): 1486-99. Available from: https://doi.org/10.1158/0008-5472.CAN-20-2828 DOI: https://doi.org/10.1158/0008-5472.CAN-20-2828
McNair C., Xu K., Mandigo A.C., Benelli M., Leiby B., Rodrigues D., et al. Differential impact of RB status on E2F1 reprogramming in human cancer. J Clin Invest [Internet]. 2018 Jan 2; 128 (1): 341-58. Available from: https://doi.org/10.1172/JCI93566 DOI: https://doi.org/10.1172/JCI93566
Kaelin Jr W.G. Functions of the retinoblastoma protein. Bioessays. 1999; 21 (11): 950-8. DOI: https://doi.org/10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D
Shieh Y., Shiah S., Jeng H., Lee H., Wu C., Chang L. DNA methyltransferase 1 expression and promoter methylation of E-cadherin in mucoepidermoid carcinoma. Cancer: Interdisciplinary International Journal of the American Cancer Society. 2005; 104 (5): 1013-21. DOI: https://doi.org/10.1002/cncr.21278
Published
Issue
Section
License
Copyright (c) 2022 CC-BY-NC-SA 4.0
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
ODOVTOS - Int. J. Dent. Sc. endorses CC BY-NC-SA
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms. CC BY-NC-SA includes the following elements:
BY: credit must be given to the creator.
NC: Only noncommercial uses of the work are permitted.
SA: Adaptations must be shared under the same terms.
